Collegium Pharmaceutical (COLL) Stock Price, News & Analysis

Company Overview

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S. Food and Drug Administration (FDA) in 2016, and Apadaz® (hydrocodone bitartrate and acetaminophen) tablets. Collegium also markets Rybix® ODT (oxycodone), an orally disintegrating tablet, and has rights to the fentanyl transdermal system ONSOLIS® under a distribution agreement. These products are supported by a dedicated commercial organization and are primarily available in the United States.

Headquartered in Wilmington, North Carolina, Collegium maintains research, development and manufacturing operations, including a facility in Richmond, Virginia. Since its incorporation in 2013, the company has expanded its product portfolio and pursued a pipeline of additional abuse-deterrent drug candidates, seeking to address unmet needs in both acute and chronic pain treatment.

Collegium is led by a management team with experience in specialty pharmaceuticals and regulatory affairs. Michael Thomas serves as President and Chief Executive Officer, guiding the company’s strategic direction and commercial growth initiatives. Under this leadership, Collegium continues to advance its mission of improving patient safety and outcomes through innovative drug delivery technologies.

Key Stats

• Today's Range: $38.00 to $38.86
• 50-Day Range: $29.75 to $39.59
• 52-Week Range: $23.23 to $42.29
• Volume: 93,017 shs
• Average Volume: 373,444 shs
• Market Capitalization: $1.21 billion
• P/E Ratio: 36.97
• Dividend Yield: N/A
• Price Target: $42.33
• Consensus Rating: Buy

Collegium Pharmaceutical Stock Analysis - MarketRank™

Collegium Pharmaceutical scored higher than 70% of companies evaluated by MarketBeat, and ranked 301st out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Buy

Consensus Rating

Collegium Pharmaceutical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Upside/Downside

The consensus price target for Collegium Pharmaceutical is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Collegium Pharmaceutical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: 7.12%

Earnings Growth

Earnings for Collegium Pharmaceutical are expected to grow by 7.12% in the coming year, from $5.62 to $6.02 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Collegium Pharmaceutical is 37.56, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.08.

Price to Earnings Ratio vs. Sector

The P/E ratio of Collegium Pharmaceutical is 37.56, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.04.

Price to Book Value per Share Ratio

Collegium Pharmaceutical has a P/B Ratio of 5.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

14.16% of the float of Collegium Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Collegium Pharmaceutical has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Collegium Pharmaceutical has recently decreased by 2.26%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Collegium Pharmaceutical does not currently pay a dividend.

Dividend Growth

Collegium Pharmaceutical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.0 / 5
• Environmental Score: -2.78

Percentage of Shares Shorted

14.16% of the float of Collegium Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Collegium Pharmaceutical has a short interest ratio ("days to cover") of 11.8, which indicates bearish sentiment.

Change versus previous month

Short interest in Collegium Pharmaceutical has recently decreased by 2.26%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.60

News Sentiment

Collegium Pharmaceutical has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Collegium Pharmaceutical this week, compared to 6 articles on an average week.

Search Interest

4 people have searched for COLL on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Collegium Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,084,207.00 in company stock.

Percentage Held by Insiders

Only 2.51% of the stock of Collegium Pharmaceutical is held by insiders.

COLL Stock Analysis - Frequently Asked Questions

How have COLL shares performed this year?

Collegium Pharmaceutical's stock was trading at $28.65 at the beginning of the year. Since then, COLL stock has increased by 36.3% and is now trading at $39.06.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) issued its quarterly earnings results on Thursday, May, 8th. The specialty pharmaceutical company reported $1.49 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.50 by $0.01. The business's revenue was up 22.7% compared to the same quarter last year.
Read the conference call transcript.

How will Collegium Pharmaceutical's stock buyback program work?

Collegium Pharmaceutical's Board of Directors authorized a share buyback plan on Monday, July 7th 2025, which authorizes the company to repurchase $150,000,000 in shares, according to EventVestor. This means that the company could buy up to 15.4% of its shares through open market purchases. Shares buyback plans are often a sign that the company's board of directors believes its shares are undervalued.

When did Collegium Pharmaceutical IPO?

Collegium Pharmaceutical (COLL) raised $75 million in an IPO on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

Who are Collegium Pharmaceutical's major shareholders?

Top institutional investors of Collegium Pharmaceutical include Rubric Capital Management LP (10.02%), Eventide Asset Management LLC (8.39%), Invesco Ltd. (5.03%) and Emerald Advisers LLC (2.61%). Insiders that own company stock include Joseph Ciaffoni, Colleen Tupper, Shirley R Kuhlmann, Scott Dreyer, Gino Santini, Thomas B Smith, Garen G Bohlin, Michael Thomas Heffernan and John Gordon Freund.
View institutional ownership trends.

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Collegium Pharmaceutical investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Arista Networks (ANET), Netflix (NFLX) and CrowdStrike (CRWD).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 9/12/2025
• Next Earnings (Estimated): 11/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:COLL
• CIK: 1267565
• Web: www.collegiumpharma.com
• Phone: (781) 713-3699
• Fax: N/A
• Employees: 210
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Collegium Pharmaceutical: $42.33
• High Price Target: $46.00
• Low Price Target: $37.00
• Potential Upside/Downside: +8.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.04
• Trailing P/E Ratio: 37.56
• Forward P/E Ratio: 6.95
• P/E Growth: N/A
• Net Income: $69.19 million
• Net Margins: 5.13%
• Pretax Margin: 7.50%
• Return on Equity: 97.28%
• Return on Assets: 13.87%

Debt

• Debt-to-Equity Ratio: 3.27
• Current Ratio: 1.18
• Quick Ratio: 1.10

Sales & Book Value

• Annual Sales: $631.45 million
• Price / Sales: 1.95
• Cash Flow: $12.81 per share
• Price / Cash Flow: 3.05
• Book Value: $7.10 per share
• Price / Book: 5.50

Miscellaneous

• Outstanding Shares: 31,500,000
• Free Float: 30,711,000
• Market Cap: $1.23 billion
• Optionable: Optionable
• Beta: 0.63